Immunocore Holdings (IMCR) Shares Outstanding (Diluted Average) (2021 - 2026)
Immunocore Holdings' (IMCR) quarterly Shares Outstanding (Diluted Average) came in at $52.9 million in Q1 2026, up 1.9% year-on-year from $51.9 million in Q1 2025, and up 5.14% quarter-over-quarter from $50.3 million in Q4 2025.
Immunocore Holdings (IMCR) Shares Outstanding (Diluted Average) (2021 - 2026) Analysis & Trends
Immunocore Holdings has disclosed Shares Outstanding (Diluted Average) across 6 years of filings, most recently posting $52.9 million for Q1 2026.
- Shares Outstanding (Diluted Average) for Q1 2026 came in at $52.9 million, up 1.9% year-over-year; the trailing twelve-month figure through Mar 2026 was $52.9 million (up 1.9% YoY), and the FY2025 annual result was $50.3 million, up 0.71% from the prior year.
- Shares Outstanding (Diluted Average) came in at $52.9 million for Q1 2026 at Immunocore Holdings, up from $50.3 million in the prior quarter.
- In the past five years, Shares Outstanding (Diluted Average) ranged from a high of $53.6 million in Q4 2022 to a low of $48.2 million in Q1 2023.
- The 5-year median for Shares Outstanding (Diluted Average) is $50.1 million (2024), against an average of $50.5 million.
- Across the five-year window, Shares Outstanding (Diluted Average) decreased 8.82% in 2023 and advanced 8.5% in 2024, its largest moves.
- Immunocore Holdings' Shares Outstanding (Diluted Average) stood at $53.6 million in 2022, then fell by 8.82% to $48.9 million in 2023, then rose by 2.25% to $50.0 million in 2024, then grew by 0.71% to $50.3 million in 2025, then rose by 5.14% to $52.9 million in 2026.
- The last three Shares Outstanding (Diluted Average) figures came in at $52.9 million (Q1 2026), $50.3 million (Q4 2025), and $50.3 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares (Diluted Avg.) (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 767,934.24 Bn | 767,934.20 Bn | - | - |
| 2 | Belite Bio | 55,234.00 Bn | 55,234.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,823.14 Bn | 17,823.14 Bn | - | 4,489.46 Bn |
| 4 | Legend Biotech | 3,624.50 Bn | 3,624.21 Bn | 242.10 Mn | 810.00 |
| 5 | Akari Therapeutics | 1,745.73 Bn | 1,745.73 Bn | - | 118.76 Bn |
| 6 | Evaxion A | 1,540.85 Bn | 1,540.84 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | 1.48 Bn |
| 8 | Vertex Pharmaceuticals | 112.57 Bn | 105.33 Bn | 2.59 Bn | 256.30 Mn |
| 9 | Abivax | 93.46 Bn | 93.46 Bn | - | 92.44 Mn |
| 10 | Immunocore Holdings | 1.46 Bn | 616.35 Mn | 106.24 Mn | 52.93 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52.93 Mn |
| Dec 31, 2025 | 50.35 Mn |
| Sep 30, 2025 | 50.26 Mn |
| Jun 30, 2025 | 50.19 Mn |
| Mar 31, 2025 | 51.95 Mn |
| Dec 31, 2024 | 49.99 Mn |
| Sep 30, 2024 | 52.81 Mn |
| Jun 30, 2024 | 49.94 Mn |
| Mar 31, 2024 | 49.88 Mn |
| Dec 31, 2023 | 48.89 Mn |
| Sep 30, 2023 | 48.67 Mn |
| Jun 30, 2023 | 48.69 Mn |
| Mar 31, 2023 | 48.18 Mn |
| Dec 31, 2022 | 53.62 Mn |
| Dec 31, 2021 | 57.28 Mn |